At a time when Covid cases are surging in several nations, Hyderabad-based Hetero Group has emerged as the first pharma player in the world to bag WHO’s prequalification of medicines programme for its generic version of oral Covid treatment, Nirmatrelvir, which along with Ritonavir is used in Pfizer’s oral drug, Paxlovid.
